Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Public ClinicalTrials.gov record NCT00454649. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose-Finding Study Of The Anti-Angiogenesis Agent, AG-013736, In Combinations Of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, Gemcitabine/Cisplatin and Pemetrexed/Cisplatin In Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT00454649
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Interventions
- Axitinib + Capecitabine (Cohort 6) Drug
- Axitinib + Capecitabine (Cohort 7) Drug
- Axitinib + Docetaxel (Cohort 5) Drug
- Axitinib + Docetaxel + Carboplatin (Cohort 4a) Drug
- Axitinib + Gemcitabine + Cisplatin (Cohort 8) Drug
- Axitinib + Paclitaxel (Cohort 4) Drug
- Axitinib + Paclitaxel + Carboplatin (Cohort 1) Drug
- Axitinib + Paclitaxel + Carboplatin (Cohort 2) Drug
- Axitinib + Paclitaxel + Carboplatin (Cohort 3) Drug
- Axitinib + Pemetrexed + Cisplatin (Cohort 9) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2005
- Primary completion
- Jul 31, 2009
- Completion
- Mar 31, 2011
- Last update posted
- Apr 3, 2012
2005 – 2011
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Augusta | Georgia | 30909 | — |
| Pfizer Investigational Site | Augusta | Georgia | 30912 | — |
| Pfizer Investigational Site | Harvey | Illinois | 60426-4265 | — |
| Pfizer Investigational Site | Harvey | Illinois | 60426 | — |
| Pfizer Investigational Site | Tinley Park | Illinois | 60477 | — |
| Pfizer Investigational Site | Hobart | Indiana | 46342 | — |
| Pfizer Investigational Site | Munster | Indiana | 46321 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19111 | — |
| Pfizer Investigational Site | Houston | Texas | 77030-4009 | — |
| Pfizer Investigational Site | Kennewick | Washington | 99336 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00454649, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2012 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00454649 live on ClinicalTrials.gov.